Verrica Pharmaceuticals Reports Positive Phase 2 Results for VP-315 in Basal Cell Carcinoma
Reuters
Nov 10
Verrica Pharmaceuticals Reports Positive Phase 2 Results for <a href="https://laohu8.com/S/VP..UK">VP</a>-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc. has announced new data from its Phase 2 clinical trial evaluating VP-315 (ruxotemitide), a novel oncolytic peptide immunotherapy for basal cell carcinoma $(BCC)$. The results were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer, held November 5-9, 2025. Findings from the exploratory analysis indicate that VP-315 reprograms the tumor microenvironment by increasing cytotoxic T-cell infiltration and reducing immunosuppressive regulatory T-cells. The data also show a 97% calculated objective response rate and a 51% complete histologic clearance rate. VP-315 is administered intratumorally and is being developed as a potential first-in-class, non-surgical immunotherapeutic option for patients with BCC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571929-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.